| pubmed-article:15262459 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15262459 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:15262459 | lifeskim:mentions | umls-concept:C0011860 | lld:lifeskim |
| pubmed-article:15262459 | lifeskim:mentions | umls-concept:C0679199 | lld:lifeskim |
| pubmed-article:15262459 | lifeskim:mentions | umls-concept:C0650607 | lld:lifeskim |
| pubmed-article:15262459 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:15262459 | pubmed:dateCreated | 2004-7-20 | lld:pubmed |
| pubmed-article:15262459 | pubmed:abstractText | The clinical progression of type 2 diabetes mellitus (DM) is well understood. Glycemic control gradually deteriorates, and progression of DM eventually leads to an increased risk for microvascular and macrovascular complications. Reassessment of current insulin treatment strategies leading to restoration of glycemic control is essential to prevent or stop the progression of type 2 DM and its complications. | lld:pubmed |
| pubmed-article:15262459 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15262459 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15262459 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15262459 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15262459 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15262459 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15262459 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15262459 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:15262459 | pubmed:issn | 0149-2918 | lld:pubmed |
| pubmed-article:15262459 | pubmed:author | pubmed-author:DaileyGeorgeG | lld:pubmed |
| pubmed-article:15262459 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15262459 | pubmed:volume | 26 | lld:pubmed |
| pubmed-article:15262459 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15262459 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15262459 | pubmed:pagination | 889-901 | lld:pubmed |
| pubmed-article:15262459 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:15262459 | pubmed:meshHeading | pubmed-meshheading:15262459... | lld:pubmed |
| pubmed-article:15262459 | pubmed:meshHeading | pubmed-meshheading:15262459... | lld:pubmed |
| pubmed-article:15262459 | pubmed:meshHeading | pubmed-meshheading:15262459... | lld:pubmed |
| pubmed-article:15262459 | pubmed:meshHeading | pubmed-meshheading:15262459... | lld:pubmed |
| pubmed-article:15262459 | pubmed:meshHeading | pubmed-meshheading:15262459... | lld:pubmed |
| pubmed-article:15262459 | pubmed:meshHeading | pubmed-meshheading:15262459... | lld:pubmed |
| pubmed-article:15262459 | pubmed:meshHeading | pubmed-meshheading:15262459... | lld:pubmed |
| pubmed-article:15262459 | pubmed:meshHeading | pubmed-meshheading:15262459... | lld:pubmed |
| pubmed-article:15262459 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15262459 | pubmed:articleTitle | New strategies for basal insulin treatment in type 2 diabetes mellitus. | lld:pubmed |
| pubmed-article:15262459 | pubmed:affiliation | Division of Diabetes and Endocrinology, Scripps Clinic, La Jolla, California 92037, USA. gdailey@scrippsclinic.com | lld:pubmed |
| pubmed-article:15262459 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15262459 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15262459 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15262459 | lld:pubmed |
